Your browser is no longer supported. Please, upgrade your browser.
AGTC Applied Genetic Technologies Corporation daily Stock Chart
Applied Genetic Technologies Corporation
Index- P/E- EPS (ttm)-2.17 Insider Own0.30% Shs Outstand25.79M Perf Week20.66%
Market Cap130.88M Forward P/E- EPS next Y-1.99 Insider Trans0.00% Shs Float22.69M Perf Month-0.72%
Income-45.90M PEG- EPS next Q-0.53 Inst Own78.00% Short Float5.96% Perf Quarter-10.88%
Sales2.50M P/S52.35 EPS this Y90.90% Inst Trans9.82% Short Ratio3.25 Perf Half Y88.66%
Book/sh3.81 P/B1.44 EPS next Y-2.60% ROA-21.10% Target Price- Perf Year52.08%
Cash/sh3.54 P/C1.55 EPS next 5Y- ROE-26.40% 52W Range2.29 - 10.42 Perf YTD21.46%
Dividend- P/FCF- EPS past 5Y37.20% ROI-5.60% 52W High-49.14% Beta2.44
Dividend %- Quick Ratio6.50 Sales past 5Y105.80% Gross Margin- 52W Low131.44% ATR0.46
Employees85 Current Ratio6.50 Sales Q/Q-100.00% Oper. Margin- RSI (14)49.79 Volatility8.88% 9.28%
OptionableYes Debt/Eq0.00 EPS Q/Q-180.10% Profit Margin- Rel Volume0.37 Prev Close5.49
ShortableYes LT Debt/Eq0.00 EarningsSep 09 BMO Payout- Avg Volume415.67K Price5.30
Recom1.70 SMA201.43% SMA50-3.27% SMA2007.06% Volume66,335 Change-3.46%
Jun-23-20Initiated Cantor Fitzgerald Overweight $14
Jan-28-20Initiated ROTH Capital Buy
Jan-27-20Initiated ROTH Capital Buy
Sep-27-19Upgrade BMO Capital Markets Market Perform → Outperform $5 → $9
Sep-27-19Reiterated H.C. Wainwright Buy $12 → $18
Sep-06-19Initiated Janney Buy $13
Sep-14-17Reiterated Stifel Buy $15 → $12
May-11-17Reiterated Stifel Buy $18 → $15
Mar-15-17Initiated Rodman & Renshaw Buy $16
Nov-09-16Upgrade ROTH Capital Neutral → Buy
Nov-09-16Reiterated Wedbush Outperform $20 → $17
Sep-13-16Reiterated Wedbush Outperform $36 → $20
Sep-13-16Reiterated Stifel Buy $29 → $24
Sep-13-16Downgrade Wells Fargo Outperform → Market Perform
Sep-13-16Downgrade ROTH Capital Buy → Neutral
Sep-13-16Downgrade Cantor Fitzgerald Buy → Hold
Feb-09-16Reiterated Stifel Buy $32 → $29
Dec-04-15Initiated Wells Fargo Outperform
Jul-22-15Initiated Chardan Capital Markets Buy $25
Jul-06-15Reiterated Cantor Fitzgerald Buy $28 → $32
Sep-12-20 09:20AM  
Sep-09-20 07:00AM  
Sep-03-20 04:05PM  
Sep-02-20 04:05PM  
Aug-25-20 07:00AM  
Aug-12-20 07:00AM  
Aug-04-20 07:00AM  
Jul-22-20 07:00AM  
Jul-14-20 06:47AM  
Jul-07-20 09:11PM  
Jun-26-20 12:00PM  
Jun-24-20 08:40AM  
Jun-23-20 04:05PM  
Jun-22-20 07:00AM  
Jun-16-20 04:01PM  
Jun-15-20 07:00AM  
Jun-10-20 11:30AM  
May-26-20 10:50AM  
May-25-20 12:00PM  
May-20-20 07:00AM  
May-15-20 06:24AM  
May-13-20 10:45AM  
May-12-20 08:00AM  
May-06-20 07:00AM  
Apr-28-20 12:34PM  
Apr-22-20 07:20AM  
Mar-24-20 12:00PM  
Mar-16-20 07:00AM  
Feb-19-20 07:00AM  
Feb-16-20 08:50AM  
Feb-06-20 08:06PM  
Feb-05-20 04:36PM  
Jan-28-20 07:30AM  
Jan-23-20 07:00AM  
Jan-22-20 04:01PM  
Jan-21-20 07:00AM  
Jan-10-20 10:08AM  
Jan-09-20 10:02AM  
Jan-08-20 04:01PM  
Dec-19-19 09:17AM  
Dec-17-19 07:36PM  
Dec-04-19 08:19PM  
Dec-03-19 07:59AM  
Dec-02-19 04:35PM  
Nov-12-19 05:55PM  
Nov-06-19 07:00AM  
Nov-05-19 07:00AM  
Oct-31-19 06:38AM  
Oct-21-19 07:00AM  
Oct-01-19 07:30AM  
Sep-30-19 09:29PM  
Sep-26-19 05:35PM  
Sep-25-19 04:05PM  
Sep-19-19 10:30AM  
Sep-18-19 04:05PM  
Sep-16-19 06:23AM  
Sep-02-19 10:30AM  
Aug-28-19 07:00AM  
Aug-14-19 07:30AM  
Aug-07-19 07:00AM  
Jul-24-19 01:54PM  
Jul-23-19 07:00AM  
Jul-19-19 09:41AM  
Jul-17-19 03:33PM  
Jul-11-19 09:05AM  
Jul-10-19 05:53PM  
Jul-08-19 06:02PM  
Jul-05-19 12:04PM  
Jun-28-19 10:10AM  
Jun-25-19 08:00AM  
Jun-24-19 05:53PM  
Jun-20-19 09:01AM  
Jun-18-19 07:00AM  
Jun-17-19 06:17PM  
Jun-14-19 05:25PM  
Jun-13-19 05:46PM  
Jun-11-19 06:18PM  
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. The company also has initiated one preclinical program in otology and three preclinical programs in targeting central nervous system disorders, including one in adrenoleukodystrophy. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited and University of Florida; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Krol Patrick Johan Hendrik10% OwnerDec 26Sale5.2481,162425,2891,780,762Dec 30 04:33 PM
Krol Patrick Johan Hendrik10% OwnerNov 19Buy2.792,5447,0981,861,924Nov 26 05:17 PM